Maakaron, J. E., Feldman, T. A., Fehniger, T. A., Shah, G. L., Mehta, A., Modi, D., Mei, M. G., Sauter, C., Khanal, R., Barta, S. K., Maly, J., Emig, M., Wunderle, L., Overesch, A., Pietzko, K., Vasile, A., Rubel, J., Graef, T., Raymon, H., Moskowitz, A. J. (2025). Results from the completed dose-finding part of phase 2 study of the innate cell engager acimtamig (AFM13) in combination with AlloNK (AB-101) in relapsed or refractory classical Hodgkin lymphoma (LuminICE-203).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.7008